ALMONTY INDUSTRIES INC

ALM refers to the common stock of Alumis Inc., a clinical-stage biopharmaceutical company. The ticker ALM trades on a major U.S. exchange, giving investors exposure to a company focused on developing oral therapies for autoimmune diseases. Like other biotech stocks, ALM's value is closely tied to clinical trial progress, regulatory milestones, and cash position rather than current commercial revenue.

Recent price movement for ALM can be tracked through the latest quote and performance chart displayed on this page. Because Alumis is a clinical-stage biotech, the shares may react sharply to pipeline news, financing updates, or sector sentiment. For the most current performance figures, including daily and year-to-date changes, refer to the live data shown above.

Valuation for a clinical-stage company like ALM is often assessed differently from profitable firms. Since Alumis may not have meaningful earnings or revenue yet, investors may look at cash reserves, projected cash runway, pipeline asset value, and comparable biotech transactions. Traditional metrics such as the P/E ratio may not be meaningful, so review the financial statements and latest disclosures before drawing conclusions.

Key metrics for ALM include cash and cash equivalents, operating expenses, research and development spending, and net loss, since the company is likely pre-revenue. Investors also monitor cash runway, share count, and any partnership or milestone payments. These figures help assess how long Alumis can fund its clinical programs and whether additional financing may be needed.

ALM shares are bought and sold through regulated U.S. stock exchanges during standard market hours. Individual investors typically access trading through a brokerage account. The exact exchange listing and trading hours are shown in the security details on this page. Extended-hours trading may also be available through some brokers, though liquidity can be lower outside regular sessions.

As a clinical-stage biotech, ALM faces risks such as clinical trial failure, regulatory delays, competition, and the need for additional capital. Share prices can be volatile around data readouts or financing announcements. Broader market and sector risks also apply. Reviewing the company's risk factors in its SEC filings can provide a clearer picture of the specific challenges Alumis faces.